- Report
- April 2026
- 144 Pages
Global
From €3594EUR$3,950USD£3,069GBP
- Report
- January 2026
- 140 Pages
Global
From €3594EUR$3,950USD£3,069GBP
- Report
- April 2026
- 192 Pages
Global
From €4544EUR$4,995USD£3,881GBP
- Report
- September 2025
- 150 Pages
Global
From €4413EUR$4,850USD£3,769GBP
- Report
- August 2025
- 150 Pages
Global
From €4413EUR$4,850USD£3,769GBP
- Report
- October 2025
- 160 Pages
Global
From €2875EUR$3,160USD£2,455GBP
€3594EUR$3,950USD£3,069GBP
- Report
- November 2025
- 203 Pages
Global
From €4504EUR$4,950USD£3,846GBP
- Report
- November 2025
- 138 Pages
Global
From €3139EUR$3,450USD£2,681GBP
- Report
- June 2026
- 200 Pages
United States
From €2720EUR$2,990USD£2,323GBP
- Report
- April 2026
- 149 Pages
North America
From €2729EUR$2,999USD£2,330GBP
€3638EUR$3,999USD£3,107GBP
- Report
- April 2026
- 150 Pages
North America
From €2729EUR$2,999USD£2,330GBP
€3638EUR$3,999USD£3,107GBP
- Report
- March 2026
- 210 Pages
United States
From €4413EUR$4,850USD£3,769GBP
- Report
- February 2026
- 150 Pages
United States
From €4413EUR$4,850USD£3,769GBP
- Report
- November 2025
- 88 Pages
Middle East, Africa
From €3139EUR$3,450USD£2,681GBP
- Report
- November 2025
- 109 Pages
Asia Pacific
From €3594EUR$3,950USD£3,069GBP
- Report
- November 2025
- 114 Pages
Europe
From €3594EUR$3,950USD£3,069GBP
- Report
- November 2025
- 106 Pages
North America
From €3139EUR$3,450USD£2,681GBP
- Report
- October 2024
- 220 Pages
Global
From €4366EUR$4,799USD£3,729GBP
- Report
- August 2018
- 340 Pages
Global
From €3183EUR$3,499USD£2,719GBP
- Report
- October 2024
- 298 Pages
Global
From €4504EUR$4,950USD£3,846GBP

Neuropathic pain is a type of chronic pain caused by damage to the nervous system. It is often described as a burning, tingling, or shooting sensation. Analgesics are medications used to reduce or eliminate pain. Neuropathic pain is often treated with a combination of analgesics, including non-steroidal anti-inflammatory drugs (NSAIDs), opioids, and anticonvulsants. Other treatments may include physical therapy, nerve blocks, and electrical stimulation.
The neuropathic pain market is a rapidly growing segment of the analgesics market. It is driven by the increasing prevalence of chronic pain conditions, such as diabetes, cancer, and multiple sclerosis. The market is expected to benefit from the development of novel treatments, such as gene therapy and stem cell therapy.
Some companies in the neuropathic pain market include Pfizer, Johnson & Johnson, GlaxoSmithKline, Novartis, and Eli Lilly. Show Less Read more